Iopofosine I 131: Compelling Phase 2 Signal in BTKi-Refractory WM, But Pivotal Evidence Remains Unbuilt

Cellectar's Iopofosine I 131 Shows Strong Efficacy in BTKi-Resistant WM

Cellectar Biosciences announced compelling efficacy data from a subset analysis of its Phase 2 CLOVER WaM clinical trial for iopofosine I 131. The data, to be presented at the International Workshop for Waldenström Macroglobulinemia (IWWM), supports iopofosine I 131 as a potential treatment for Waldenström Macroglobulinemia (WM) patients who are refractory or resistant to BTK inhibitor therapy. The analysis demonstrated a Major Response Rate of 79.2%, an Overall Response Rate of 87.5%, and a Duration of Response exceeding 16 months in patients treated immediately post-BTKi therapy. These results reinforce the company's plans to advance iopofosine I 131 into a Phase 3 confirmatory trial and submit for U.S. Accelerated Market Approval in 1H27, with potential approval by the end of 2027 due to its Breakthrough Therapy Designation.

• The subset analysis of the CLOVER WaM study demonstrated robust efficacy for iopofosine I 131 in a heavily pretreated Waldenström Macroglobulinemia patient population. Specifically, patients refractory or resistant to BTK inhibitor therapy achieved a Major Response Rate (MRR) of 79.2% and an Overall Response Rate (ORR) of 87.5%. These figures highlight the drug's significant therapeutic potential in a challenging patient group with high unmet medical need.
• A key finding from the CLOVER WaM subset analysis was the impressive Duration of Response (DoR) exceeding 16 months. This sustained response was observed in patients who received iopofosine I 131 immediately following BTK inhibitor therapy, after at least two prior lines of treatment. This specific patient population represents a particularly difficult-to-treat group, underscoring the drug's potential to provide meaningful, long-lasting benefits.
• Based on these compelling Phase 2 data, Cellectar Biosciences is on track to initiate a confirmatory Phase 3 clinical trial in early 2027. The company also plans to submit a New Drug Application (NDA) for accelerated approval in the first half of 2027. Given iopofosine I 131's existing Breakthrough Therapy Designation, a six-month review period is anticipated, potentially leading to market approval by the end of 2027, addressing a significant unmet need.

Targeting the Unmet Need in BTKi-Resistant WM

Despite meaningful advances driven by BTK inhibitor (BTKi) adoption, several patient populations with Waldenström macroglobulinemia (WM) remain inadequately served, and the field is actively targeting these gaps through novel agents and combination strategies. Key challenges include acquired resistance to covalent BTKi, the difficulty of achieving deep remission, and the burden of indefinite continuous therapy.

• BTKi-resistant and BTKi-exposed patients: Resistance to covalent BTKi most commonly arises through BTK C481 substitutions and activating PLCG2 mutations. Non-covalent BTKi such as pirtobrutinib bind BTK independently of C481, enabling activity in patients who have progressed on covalent agents. In a retrospective analysis of 76 relapsed/refractory LPL/WM patients treated with venetoclax, 82% had received a prior covalent BTKi, and prior BTKi exposure was the only factor independently associated with inferior PFS in multivariate analysis (hazard ratio 2.97, p = 0.012), underscoring this as a high-priority unmet need.

• Patients requiring deep remission and time-limited therapy: Complete response remains elusive with BTKi monotherapy, and continuous therapy carries risks of cumulative toxicity, acquired resistance, and financial burden. A phase II study of zanubrutinib plus ixazomib and dexamethasone (ZID) in newly diagnosed WM achieved a deep remission rate of 45.8% (VGPR or CR) and an overall response rate of 100%, with an estimated median PFS of 40 months (95% CI: 35.5–44.5), demonstrating that proteasome inhibitor-based combinations may enable finite-duration BTKi therapy.

• CXCR4-mutated and MYD88 wild-type patients: Efficacy of covalent BTKi is compromised in patients harboring CXCR4 mutations or MYD88 wild-type genotype. In the ZID phase II study, CXCR4 mutation status did not significantly impact deep remission rates (40% vs. 50%, P = 0.594), suggesting combination regimens may partially mitigate this historically poor-prognosis subgroup. Long-term venetoclax follow-up data similarly showed that CXCR4 mutations did not impact PFS or treatment-free survival, identifying venetoclax-based approaches as a relevant option for this population.

• Heavily pretreated patients with limited salvage options: In the multicenter venetoclax retrospective cohort, patients had received a median of 3 prior lines of therapy; venetoclax monotherapy yielded an overall response rate of 70%, a median PFS of 28.5 months, and a 2-year OS of 82%, establishing a viable salvage pathway. Retreatment with venetoclax after disease progression was feasible in a prospective cohort, with 7 of 9 retreated patients achieving at least a partial response and no BCL2 G101V resistance mutations detected.

• Patients with familial WM and specific complication risk profiles: Among 1,000 WM patients with a median follow-up of 13 years, those with a family history of WM (WM-FH) had significantly higher odds of Bing-Neel syndrome (OR 3.90; p = 0.005) and lower odds of neuropathy (OR 0.49; p = 0.03) compared to sporadic cases, though WM-FH did not impact time to first treatment, overall survival, or survival after first treatment initiation — identifying CNS-directed surveillance and management as a distinct clinical need in this subgroup.

Iopofosine I 131's Efficacy in BTKi-Refractory WM

Recent clinical investigation in Waldenström macroglobulinemia (WM) has generated meaningful long-term efficacy and safety data across both BTK inhibitor and BCL-2 inhibitor strategies. The phase III ASPEN study compared zanubrutinib with ibrutinib in patients with symptomatic WM. At a median follow-up of 44.4 months, very good partial response (VGPR) plus complete response (CR) rates were 36.3% with zanubrutinib versus 25.3% with ibrutinib in MYD88-mutant patients (cohort 1), with median progression-free survival (PFS) and overall survival not reached in either arm. From a safety standpoint, atrial fibrillation/flutter (23.5% vs. 7.9%), diarrhea (34.7% vs. 22.8%), and pneumonia (18.4% vs. 5.0%) were more frequent with ibrutinib, while neutropenia was more common with zanubrutinib (34.7% vs. 20.4%). Zanubrutinib was also associated with a lower rate of adverse event-related treatment discontinuation. A complementary pooled safety analysis of zanubrutinib monotherapy across six studies (N = 779) further characterized its tolerability profile, identifying pneumonia (11% grade ≥3), neutropenia (23% grade ≥3), and atrial fibrillation (3%) as key events of interest, with treatment discontinuations due to adverse events occurring in 10% of patients.

In the venetoclax space, a multicenter retrospective analysis evaluated 76 patients with relapsed/refractory lymphoplasmacytic lymphoma (LPL)/WM treated with venetoclax monotherapy across nine US medical centers. The overall and major response rates were 70% and 63%, respectively, with a median PFS of 28.5 months and a 2-year PFS of 57%. Median overall survival was not reached, and the 2-year overall survival rate was 82%. Prior BTK inhibitor exposure was the only factor independently associated with PFS in multivariate analysis (hazard ratio 2.97, p = 0.012). Notably, 5 patients (7%) developed laboratory tumor lysis syndrome, including 3 (4%) with clinical TLS. Separately, a prospective clinical trial of finite-duration venetoclax monotherapy in 32 previously treated WM patients reported a median PFS of 36 months and a median treatment-free survival of 43 months at a median follow-up of 81 months. Nine of 17 patients who progressed after completing venetoclax therapy were successfully retreated with venetoclax alone or in combination, with no BCL2 G101V resistance mutations detected across 52 CD19-selected bone marrow samples from 27 patients during treatment.

Earlier phase I data from a first-in-human study of venetoclax monotherapy in relapsed/refractory non-Hodgkin lymphoma, which included a WM cohort, reported a median PFS of 30.4 months and a median duration of response of 25.3 months for WM patients at a median follow-up of 38.5 months. Nonhematologic adverse events included nausea (49%), diarrhea (46%), and fatigue (44%), with decreased incidence after 1 year on therapy; hematologic adverse events were infrequent, with neutropenia, anemia, and thrombocytopenia each occurring in 17–19% of patients and no new cytopenias observed after 2 years on treatment.

Iopofosine I 131: A Beacon for BTKi-Resistant WM

The recent announcement regarding iopofosine I 131's compelling Phase 2 data in Waldenström Macroglobulinemia (WM) patients who are refractory or resistant to BTK inhibitors marks a potentially pivotal moment for this challenging B-cell malignancy. BTK inhibitors have undeniably transformed the treatment landscape for WM, offering significant efficacy and improved outcomes compared to traditional chemotherapy. However, a critical clinical challenge remains: what to do when patients progress on these therapies or cannot tolerate them. This is a substantial unmet need, as existing evidence highlights the ongoing questions surrounding optimal treatment for BTKi-resistant patients.

Iopofosine I 131's reported Major Response Rate of 79.2% and Overall Response Rate of 87.5%, with a Duration of Response exceeding 16 months in this specific post-BTKi population, are highly encouraging. These results suggest a robust activity profile in a patient segment with limited effective options. Strategically, this positions iopofosine I 131 to carve out a distinct and valuable niche, potentially becoming a go-to therapy for patients who have exhausted BTKi options. The Breakthrough Therapy Designation and the ambitious timeline for accelerated approval by 1H27, with potential market entry by the end of 2027, underscore the regulatory recognition of this urgent need and the drug's promising profile.

However, as with any emerging therapy, important considerations remain. The current data stems from a subset analysis of a Phase 2 trial, necessitating confirmation in a larger, pivotal Phase 3 study to validate these impressive results and ensure generalizability. Furthermore, a comprehensive understanding of iopofosine I 131's long-term safety profile, especially in a heavily pre-treated and vulnerable patient population, will be crucial. The competitive landscape for WM is also dynamic, with ongoing advancements in next-generation BTK inhibitors and combination regimens. While iopofosine I 131 offers a novel mechanism, continuous innovation in the BTKi space, including non-covalent options for relapsed/refractory cases, could influence its future market trajectory. Nevertheless, these early data provide a strong foundation for a much-needed therapeutic alternative, offering renewed hope for patients facing BTKi resistance.